This study will investigate BMS-986165 to assess its effects in patients with systemic lupus erythematosus (SLE). First in class to be tested in lupus, BMS-9865165 is a potent, highly-selective inhibitor of Tyrosine kinase 2 (Tyk2) that suppresses pathways implicated in lupus. Recruiting sites have contact information.
Enrollment completed as of July, 2021
To Learn More Contact
Please contact the sites directly. If there is no contact information, please email Clinical.Trials@BMS.com
ClinicalTrials.gov identifier: NCT03252587